Effect of Astragalus Injection on Platelet Function and Plasma Endothelin in Patients with Early Stage Diabetic Nephropathy
- VernacularTitle:黄芪注射液对早期糖尿病肾病患者血小板功能和血浆内皮素的影响
- Author:
Zhi-Qiang LIU
1
;
Quan-Zhi LI
;
Gui-Jun QIN
Author Information
1. The Affiliated Huaihe Hospital of Kaifeng Medical School
- From:
Chinese Journal of Integrated Traditional and Western Medicine
2001;21(4):274-276
- CountryChina
- Language:Chinese
-
Abstract:
To study the therapeutic effect of Astragalus injection (AI) in treating early stage diabetic nephropathy (DN) patients. Methods: The total of 136 early diabetic nephropathy patients were randomly divided into two groups, 50 cases in the conventional treated group and 86 in the AI treated group, the therapeutic course being 3 weeks. Levels of plasma endothelin-1 (ET-1), 24 hrs urinary albumin excretion rate (uAER), and platelet granule membrane protein (GMP-140), 6-keto-prostaglandin F1α (6-keto-PGF1α), and thromboxane B2 (TXB2) before and after treatment were determined by radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA) respectively. Moreover, the above-mentioned criteria in 26 healthy subjects were also measured for control. Results: The plasma ET-1, GMP-140, TXB2 and uAER levels in DN patients were higher, but 6-keto-PGF1α level was lower than those in healthy subjects. The above elevated criteria in DN patients could be lowered by AI treatment. Conclusion: The pathogenesis and development of DN might be closely associated with the changes of plasma ET-1 level and platelet function. Astragalus could improve the above-mentioned changes in patients of early stage DN.
